Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice.

[1]  P. Angulo,et al.  Nonalcoholic fatty liver disease. , 2002, Revista de gastroenterologia de Mexico.

[2]  G. Gores,et al.  Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. , 2003, Gastroenterology.

[3]  R. Fisher,et al.  Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values , 2003, Hepatology.

[4]  Judy Lieberman,et al.  RNA interference targeting Fas protects mice from fulminant hepatitis , 2003, Nature Medicine.

[5]  G. Gores,et al.  Cholestasis Increases Tumor Necrosis Factor-Related Apoptotis-Inducing Ligand (TRAIL)-R2/DR5 Expression and Sensitizes the Liver to TRAIL-Mediated Cytotoxicity , 2002, Journal of Pharmacology and Experimental Therapeutics.

[6]  G. Gores,et al.  Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. , 2002, Gastroenterology.

[7]  S. Friedman,et al.  Leptin in hepatic fibrosis: Evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice , 2002, Hepatology.

[8]  K. Lindor,et al.  Non‐alcoholic fatty liver disease , 2002, Journal of gastroenterology and hepatology.

[9]  R. Karim,et al.  NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome , 2002, Hepatology.

[10]  J. Maher,et al.  Anti-Fas Induces Hepatic Chemokines and Promotes Inflammation by an NF-κB-independent, Caspase-3-dependent Pathway* , 2001, The Journal of Biological Chemistry.

[11]  G. Gores,et al.  The Bile Acid Glycochenodeoxycholate Induces TRAIL-Receptor 2/DR5 Expression and Apoptosis* , 2001, The Journal of Biological Chemistry.

[12]  Y. Takei,et al.  Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals , 2001, Hepatology.

[13]  G. Marchesini,et al.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.

[14]  G. Ciliberto,et al.  Interleukin-6 Protects against Fas-mediated Death by Establishing a Critical Level of Anti-apoptotic Hepatic Proteins FLIP, Bcl-2, and Bcl-xL* , 2001, The Journal of Biological Chemistry.

[15]  G. Farrell,et al.  Etiopathogenesis of Nonalcoholic Steatohepatitis , 2001, Seminars in liver disease.

[16]  G. Marchesini,et al.  Clinical Features and Natural History of Nonalcoholic Steatosis Syndromes , 2001, Seminars in liver disease.

[17]  A. Diehl,et al.  Animal Models of Steatosis , 2001, Seminars in liver disease.

[18]  J. Friedman,et al.  Obesity in the new millennium , 2000, Nature.

[19]  K. Batts,et al.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.

[20]  M. Thun,et al.  Body-mass index and mortality in a prospective cohort of U.S. adults. , 1999, The New England journal of medicine.

[21]  G. Gores,et al.  Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. , 1999, Gastroenterology.

[22]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[23]  G. Gores,et al.  Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. , 1999, The Journal of clinical investigation.

[24]  S. Nagata,et al.  Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand , 1998, Nature Medicine.

[25]  L. Kaplan Leptin, obesity, and liver disease. , 1998, Gastroenterology.

[26]  H. Jaeschke,et al.  Parenchymal cell apoptosis as a signal for sinusoidal sequestration and transendothelial migration of neutrophils in murine models of endotoxin and fas‐antibody–induced liver injury , 1998, Hepatology.

[27]  V. Dixit,et al.  Death receptors: signaling and modulation. , 1998, Science.

[28]  G. Gores,et al.  Nuclear serine protease activity contributes to bile acid-induced apoptosis in hepatocytes. , 1995, The American journal of physiology.

[29]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: an expanded clinical entity. , 1994, Gastroenterology.

[30]  L. Groop,et al.  Role of free fatty acids and insulin in determining free fatty acid and lipid oxidation in man. , 1991, The Journal of clinical investigation.

[31]  R. DeFronzo,et al.  Effect of fatty acids on glucose production and utilization in man. , 1983, The Journal of clinical investigation.

[32]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.